keyword
https://read.qxmd.com/read/37323920/effect-of-apremilast-on-lps-induced-immunomodulation-and-inflammation-via-activation-of-nrf2-ho-1-pathways-in-rat-lungs
#21
JOURNAL ARTICLE
Naif O Al-Harbi, Faisal Imam, Mohammad Matar Al-Harbi, Wajhul Qamar, Khaldoon Aljerian, Md Khalid Anwer, Mohammed Alharbi, Sultan Almudimeegh, Abdullah S Alhamed, Ali A Alshamrani
Lipopolysaccharides (LPS), the lipid component of gram-negative bacterial cell wall, is recognized as the key factor in acute lung inflammation and is found to exhibit severe immunologic reactions. Phosphodiesterase-4 (PDE-4) inhibitor: "apremilast (AP)" is an immune suppressant and anti-inflammatory drug which introduced to treat psoriatic arthritis. The contemporary experiment designed to study the protective influences of AP against LPS induced lung injury in rodents. Twenty-four (24) male experimental Wistar rats selected, acclimatized, and administered with normal saline, LPS, or AP + LPS respectively from 1 to 4 groups...
July 2023: Saudi Pharmaceutical Journal: SPJ: the Official Publication of the Saudi Pharmaceutical Society
https://read.qxmd.com/read/37257579/roflumilast-ameliorates-ovariectomy-induced-depressive-like-behavior-in-rats-via-activation-of-ampk-mtor-ulk1-dependent-autophagy-pathway
#22
JOURNAL ARTICLE
Eman S Zaki, Rabab H Sayed, Muhammed A Saad, Muhammed F El-Yamany
AIMS: Roflumilast, a well-known phosphodiesterase-4 (PDE-4) inhibitor, possess an anti-inflammatory activity with approved indications in chronic obstructive pulmonary disease. This study aimed to evaluate the neuroprotective role of roflumilast in ovariectomy (OVX)-induced depressive-like behavior in female rats and to shed light on a potential autophagy enhancing effect. MAIN METHODS: Rats were randomly divided into four groups: sham, OVX, OVX + roflumilast (1 mg/kg, p...
May 29, 2023: Life Sciences
https://read.qxmd.com/read/37209391/efficacy-and-safety-of-nail-psoriasis-targeted-therapies-a-systematic-review
#23
Jonathan K Hwang, Jose W Ricardo, Shari R Lipner
INTRODUCTION: Nail changes are frequent clinical findings in patients with cutaneous psoriasis and psoriatic arthritis, often causing significant impairments in quality of life. Numerous targeted therapies have been previously studied for treatment of nail psoriasis, however, newer agents have not been captured in prior systematic reviews. With over 25 new studies published since 2020, the landscape of nail psoriasis systemic treatments is rapidly evolving, warranting analysis of recently approved therapies...
September 2023: American Journal of Clinical Dermatology
https://read.qxmd.com/read/37004962/phosphodiesterase-pde-4-inhibition-boosts-schwann-cell-myelination-in-a-3d-regeneration-model
#24
JOURNAL ARTICLE
Melissa Schepers, Afonso Malheiro, Adrián Seijas Gamardo, Niels Hellings, Jos Prickaerts, Lorenzo Moroni, Tim Vanmierlo, Paul Wieringa
Phosphodiesterase 4 (PDE4) inhibitors have been extensively researched for their anti-inflammatory and neuroregenerative properties. Despite the known neuroplastic and myelin regenerative properties of nonselective PDE4 inhibitors on the central nervous system, the direct impact on peripheral remyelination and subsequent neuroregeneration has not yet been investigated. Therefore, to examine the possible therapeutic effect of PDE4 inhibition on peripheral glia, we assessed the differentiation of primary rat Schwann cells exposed in vitro to the PDE4 inhibitor roflumilast...
March 31, 2023: European Journal of Pharmaceutical Sciences
https://read.qxmd.com/read/36865738/camp-pde-signaling-in-copd-review-of-cellular-molecular-and-clinical-features
#25
REVIEW
Yazdan Hasani Nourian, Jafar Salimian, Ali Ahmadi, Zahra Salehi, Mehrdad Karimi, Alireza Emamvirdizadeh, Sadegh Azimzadeh Jamalkandi, Mostafa Ghanei
Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death among non-contagious diseases in the world. PDE inhibitors are among current medicines prescribed for COPD treatment of which, PDE-4 family is the predominant PDE isoform involved in hydrolyzing cyclic adenosine monophosphate (cAMP) that regulates the inflammatory responses in neutrophils, lymphocytes, macrophages and epithelial cells The aim of this study is to investigate the cellular and molecular mechanisms of cAMP-PDE signaling, as an important pathway in the treatment management of patients with COPD...
July 2023: Biochemistry and Biophysics Reports
https://read.qxmd.com/read/36710269/intestinal-dysbiosis-exacerbates-the-pathogenesis-of-psoriasis-like-phenotype-through-changes-in-fatty-acid-metabolism
#26
JOURNAL ARTICLE
Qixiang Zhao, Jiadong Yu, Hong Zhou, Xiaoyan Wang, Chen Zhang, Jing Hu, Yawen Hu, Huaping Zheng, Fanlian Zeng, Chengcheng Yue, Linna Gu, Zhen Wang, Fulei Zhao, Pei Zhou, Haozhou Zhang, Nongyu Huang, Wenling Wu, Yifan Zhou, Jiong Li
The intestinal microbiota has been associated with host immunity as well as psoriasis; however, the mechanism of intestinal microbiota regulating psoriasis needs to be demonstrated systematically. Here, we sought to examine its role and mechanism of action in the pathogenesis of psoriasis. We found that the severity of psoriasis-like skin phenotype was accompanied by changes in the composition of the intestinal microbiota. We performed co-housing and fecal microbial transplantation (FMT) experiments using the K14-VEGF transgenic mouse model of psoriasis and demonstrated that the transfer of intestinal microbiota from mice with severe psoriasis-like skin phenotype exacerbated psoriasiform skin inflammation in mice with mild symptoms, including increasing the infiltration and differentiation of Th17, and increased the abundance of Prevotella, while decreasing that of Parabacteroides distasonis, in the colon...
January 30, 2023: Signal Transduction and Targeted Therapy
https://read.qxmd.com/read/36641009/guidelines-of-care-for-the-management-of-atopic-dermatitis-in-adults-with-topical-therapies
#27
JOURNAL ARTICLE
Robert Sidbury, Ali Alikhan, Lionel Bercovitch, David E Cohen, Jennifer M Darr, Aaron M Drucker, Lawrence F Eichenfield, Lindsy Frazer-Green, Amy S Paller, Kathryn Schwarzenberger, Jonathan I Silverberg, Anne Marie Singh, Peggy A Wu, Dawn M R Davis
BACKGROUND: New evidence has emerged since the 2014 guidelines that further informs the management of atopic dermatitis (AD) with topical therapies. These guidelines update the 2014 recommendations for management of AD with topical therapies. OBJECTIVE: To provide evidence-based recommendations related to management of AD in adults using topical treatments. METHODS: A multidisciplinary workgroup conducted a systematic review and applied the GRADE (Grading of Recommendations, Assessment, Development, and Evaluations) approach for assessing the certainty of evidence and formulating and grading recommendations...
July 2023: Journal of the American Academy of Dermatology
https://read.qxmd.com/read/36621953/pde4-inhibitor-roflumilast-modulates-inflammation-and-lipid-accumulation-in-pcos-mice-to-improve-ovarian-function-and-reduce-dhea-induced-granulosa-cell-apoptosis-in-vitro
#28
JOURNAL ARTICLE
Xiaowei Ji, Yao Ye, Lin Wang, Suying Liu, Xi Dong
This study was implemented to address the role of Roflumilast in polycystic ovary syndrome (PCOS) as well as to discuss its reaction mechanism in vivo and in vitro. In vivo, mice were administrated with 6 mg dehydroepiandrosterone (DHEA) per 100 g body weight and fed with 60% high fat diet to induce PCOS. The expression of phosphodiesterases 4 (PDE4) was assessed with RT-qPCR. The ovary pathology was observed by hematoxylin and eosin staining and follicles were counted. Enzyme-linked immunosorbent assay was adopted for the estimation of progesterone, testosterone and inflammatory factors and lipid accumulation was observed by Oil Red O staining...
January 9, 2023: Drug Development Research
https://read.qxmd.com/read/36610330/therapeutic-treatment-with-phosphodiesterase-4-inhibitors-alleviates-kidney-injury-and-renal-fibrosis-by-increasing-mmp-9-in-a-doxorubicin-induced-nephrotoxicity-mouse-model
#29
JOURNAL ARTICLE
Walyson Coelho Costa, Vinícius Amorim Beltrami, Gabriel Henrique Campolina-Silva, Celso Martins Queiroz-Junior, Rodrigo M Florentino, Jéssica Rayssa Machado, Débora Gonzaga Martins, William Antonio Gonçalves, Lívia Corrêa Barroso, Katia Michelle Freitas, Fernando Pedro de Souza-Neto, Franciel Batista Félix, Rafaela Fernandes da Silva, Cleida Aparecida Oliveira, Niels Olsen Saraiva Câmara, Milene Alvarenga Rachid, Mauro Martins Teixeira, Barbara Maximino Rezende, Vanessa Pinho
Nephrotic syndrome (NS) is associated with kidney dysfunction and is an important cause of morbidity and mortality in industrialized countries. Here, we evaluated the effects of the phosphodiesterase-4 (PDE-4) inhibitors rolipram and roflumilast on a doxorubicin-induced NS model. Early-stage rolipram treatment preserved glomerular filtration barrier function, as indicated by reduced serum protein and albumin loss and the prevention of hypercholesterolemia. These effects were associated with reduced glomerular and tubular lesions and abrogated renal cell apoptosis...
January 5, 2023: International Immunopharmacology
https://read.qxmd.com/read/36538948/unmet-needs-for-patients-with-seborrheic-dermatitis
#30
REVIEW
J Mark Jackson, Andrew Alexis, Matthew Zirwas, Susan Taylor
Seborrheic dermatitis (SD) is a common skin disease with signs and symptoms that may vary by skin color, associated medical conditions, environmental factors, and vehicle preference. Diagnosis of SD is based on presence of flaky, "greasy" patches, and/or thin plaques accompanied by erythema of the scalp, face, ears, chest, and groin and is associated with pruritus in many patients. The presentation may vary in different skin types and hyper- or hypopigmentation may occur, with or without erythema and minimal or no scaling...
March 2024: Journal of the American Academy of Dermatology
https://read.qxmd.com/read/36515218/targeting-anti-inflammatory-immunonanocarriers-to-human-and-murine-neutrophils-via-the-ly6-antigen-for-psoriasiform-dermatitis-alleviation
#31
JOURNAL ARTICLE
Cheng-Yu Lin, Huang-Ping Yu, Yen-Tzu Chang, Zih-Chan Lin, Ahmed Alalaiwe, Tsong-Long Hwang, Jia-You Fang
Psoriasis is a refractory and difficult-to-treat skin disorder. The neutrophil-targeting approach represents a promising option for psoriasis therapy. This study developed and examined NIMP-R14-conjugated immunonanoparticles for specific targeting to neutrophils associated with psoriasiform dermatitis. In the process, roflumilast (RFL), as a phosphodiesterase (PDE) 4 inhibitor, was encapsulated in the nanocarriers to assess the anti-inflammatory capability against primary neutrophil activation and murine psoriasiform lesion...
December 14, 2022: Biomaterials Science
https://read.qxmd.com/read/36481585/insight-into-the-pivotal-role-of-signaling-pathways-in-psoriasis-pathogenesis-potential-therapeutic-molecules-and-drug-delivery-approaches
#32
REVIEW
Yashika Tomar, Srividya Gorantla, Gautam Singhvi
Psoriasis is a multifactorial chronic autoimmune skin disorder, the exact cause of which is still under investigation. It is classified into different types displaying various histopathological features such as hyperproliferation, irregular parakeratosis and vascular infiltration of various immune cells with neutrophils in the epidermis. Over the past few decades, psoriasis pathogenesis has been thoroughly researched, leading to several advances in the treatment using small molecules and biologics. This review focuses on describing the role of various signaling pathways, including PDE-4, JAK-STAT, S1P, A3 AR and NF-κB, in psoriasis pathogenesis and associated new molecules that are either recently approved or under clinical trials...
December 5, 2022: Drug Discovery Today
https://read.qxmd.com/read/36478475/systematic-review-of-newer-agents-for-the-management-of-alopecia-areata-in-adults-janus-kinase-inhibitors-biologics-and-phosphodiesterase-4-inhibitors
#33
REVIEW
Aditya K Gupta, Tong Wang, Shruthi Polla Ravi, Mary A Bamimore, Vincent Piguet, Antonella Tosti
Management options for moderate-to-severe alopecia areata (AA) are limited owing to a lack of safe and effective treatments suitable for long-term use. However, newer agents have the potential to induce and maintain hair regrowth in patients with a better side-effects profile compared to systemic steroids or conventional systemic agents. In this article, we conducted a systematic review of newer agents, including Janus kinase (JAK) inhibitors, biologics and phosphodiesterase-4 (PDE-4) inhibitors, for the treatment of AA in adult patients evaluated in randomized controlled trials (RCTs) using the Severity of Alopecia Tool score...
April 2023: Journal of the European Academy of Dermatology and Venereology: JEADV
https://read.qxmd.com/read/36400237/long-term-treatment-with-roflumilast-improves-learning-of-fear-extinction-memory-and-anxiety-like-response-in-a-type-1-diabetes-mellitus-animal-model
#34
JOURNAL ARTICLE
Ana Paula Farias Waltrick, Ana Carolina Felipe da Silva, Bianca Andretto de Mattos, Yane Costa Chaves, Rúbia Maria Weffort de Oliveira, Jos Prickaerts, Janaína Menezes Zanoveli
Diabetic encephalopathy is related to serious damage to the Central Nervous System leading to several disturbances in memory processing and emotions. It is known that the cyclic adenosine 3',5'-monophosphate (cAMP) responsive element-binding protein (CREB) pathway participates in neuronal plasticity and prevention of neuroinflammation, as well as the mediation of learning/memory processes and emotions in brain areas such as the hippocampus (HIP) and prefrontal cortex (PFC). We aimed to investigate the effect of acute (one injection) and long-term treatment (21 days) with roflumilast (ROF; i...
November 15, 2022: Behavioural Brain Research
https://read.qxmd.com/read/36306559/the-immunomodulatory-effects-of-roflumilast-on-tachyzoite-bradyzoite-transition-in-a-murine-model-of-toxoplasma-gondii
#35
JOURNAL ARTICLE
Ahlam Elmasry, Wafaa A Aboukamar, Heba Hany, Manar S Elmehankar
Roflumilast, a phosphodiesterase 4-inhibitor (PDE-4), shows immunomodulatory and anti-inflammatory properties. It modulates cAMP and TNF-α levels that play a role in the differentiation of Toxoplasma gondii (T. gondii) tachyzoite to bradyzoite stage. Thus, the potential effect of Roflumilast on the tachyzoite-bradyzoite transition in Me49 murine toxoplasmosis using 36 female Swiss Webster mice was studied. The mice were divided into six equal groups; normal control, infected control, two groups treated earlier with Roflumilast at 5 mg/kg and 10 mg/kg, and two groups treated later with Roflumilast at 5 mg/kg and 10 mg/kg...
October 25, 2022: International Immunopharmacology
https://read.qxmd.com/read/36301752/improvement-of-head-and-neck-symptoms-in-patients-with-atopic-dermatitis-treated-with-baricitinib-based-on-five-phase-iii-clinical-trials
#36
JOURNAL ARTICLE
Andreas Wollenberg, Peter Lio, Elise Kleyn, Robert Bissonnette, Maria Jose Rueda, Marta Casillas, Yun-Fei Chen, Na Lu, Andrea Schloebe, Eric Simpson
Background: In adults with atopic dermatitis (AD), head and/or neck involvement is frequent, bothersome, and impacts quality of life, however, long-term topical corticosteroids (TCS) are contraindicated for this difficult-to-treat region. Baricitinib, an oral, selective, reversible inhibitor of Janus kinase 1/2 has demonstrated efficacy in adult patients with moderate-to-severe AD. Objectives: For this post hoc analysis, data from five Phase III trials were used to investigate the efficacy of baricitinib in patients with head and neck involvement...
July 1, 2022: European Journal of Dermatology: EJD
https://read.qxmd.com/read/36105749/advancements-in-the-treatment-of-cutaneous-lupus-erythematosus-and-dermatomyositis-a-review-of-the-literature
#37
REVIEW
Kareem G Elhage, Raymond Zhao, Mio Nakamura
BACKGROUND: Cutaneous lupus erythematosus (CLE) and dermatomyositis (DM) are autoimmune diseases that present with a wide variety of cutaneous manifestations. In both cases, first-line therapy includes topical corticosteroids. Patients may present with more widespread disease requiring systemic treatments, including corticosteroids, traditional immunosuppressants, or antimalarials. Due to their complex nature, both CLE and DM remain difficult to treat and continue to cause significant distress to patients...
2022: Clinical, Cosmetic and Investigational Dermatology
https://read.qxmd.com/read/36078904/new-and-upcoming-topical-treatments-for-atopic-dermatitis-a-review-of-the-literature
#38
REVIEW
Nikolaos Sideris, Eleni Paschou, Katerina Bakirtzi, Dimitra Kiritsi, Ilias Papadimitriou, Aikaterini Tsentemeidou, Elena Sotiriou, Efstratios Vakirlis
Atopic dermatitis (AD) is a chronic inflammatory dermatosis with periods of exacerbation and remissions. AD is characterized by intense, persistent pruritus and heterogeneity in clinical symptomatology and severity. Therapeutic goals include the amelioration of cutaneous eruptions, diminishing relapses and eventually the disease burden. To date, topical corticosteroids (TCS) and calcineurin inhibitors (TCI) have yet been deemed the mainstay of topical treatments in AD management. Nevertheless, despite their indisputable efficiency, TCS and TCI are not indicated for continuous long-term use given their safety profile...
August 24, 2022: Journal of Clinical Medicine
https://read.qxmd.com/read/36059592/type-2-inflammation-contributes-to-skin-barrier-dysfunction-in-atopic-dermatitis
#39
REVIEW
Lisa A Beck, Michael J Cork, Masayuki Amagai, Anna De Benedetto, Kenji Kabashima, Jennifer D Hamilton, Ana B Rossi
Skin barrier dysfunction, a defining feature of atopic dermatitis (AD), arises from multiple interacting systems. In AD, skin inflammation is caused by host-environment interactions involving keratinocytes as well as tissue-resident immune cells such as type 2 innate lymphoid cells, basophils, mast cells, and T helper type 2 cells, which produce type 2 cytokines, including IL-4, IL-5, IL-13, and IL-31. Type 2 inflammation broadly impacts the expression of genes relevant for barrier function, such as intracellular structural proteins, extracellular lipids, and junctional proteins, and enhances Staphylococcus aureus skin colonization...
September 2022: JID innovations
https://read.qxmd.com/read/35999453/phosphodiesterase-4d-contributes-to-angiotensin-ii-induced-abdominal-aortic-aneurysm-through-smooth-muscle-cell-apoptosis
#40
JOURNAL ARTICLE
Ran Gao, Wenjun Guo, Tianfei Fan, Junling Pang, Yangfeng Hou, Xiaohang Feng, Bolun Li, Weipeng Ge, Tianhui Fan, Tiantian Zhang, Jiakai Lu, He Jing, Mu Jin, Chen Yan, Jing Wang
Abdominal aortic aneurysm (AAA) is a permanent expansion of the abdominal aorta that has a high mortality but limited treatment options. Phosphodiesterase (PDE) 4 family members are cAMP-specific hydrolyzing enzymes and have four isoforms (PDE4A-PDE4D). Several pan-PDE4 inhibitors are used clinically. However, the regulation and function of PDE4 in AAA remain largely unknown. Herein, we showed that PDE4D expression is upregulated in human and angiotensin II-induced mouse AAA tissues using RT-PCR, western blotting, and immunohistochemical staining...
August 2022: Experimental & Molecular Medicine
keyword
keyword
92780
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.